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Abstract
Background and purposes: This study compared VMAT and IMRT plans for intact breast radiotherapy for left sided
breast cancer and evaluated the irradiated dose of planning target volume and OARs, especially focusing on heart and
coronary artery.
Materials and methods: Eleven patients with left sided breast cancer whose breast was relatively smaller (the mean
volumes is 296 cc) treated with breast-conserving surgery were prescribed radiotherapy of 50 Gy in 25 fractions using
two or four-field step and shoot IMRT (2 or 4-F IMRT), and one or two-arc VMAT (1 or 2-arc VMAT). The 10 Gy electron
boost to the tumor bed after delivery of 50 Gy was not included in the analysis. Multiple planning parameters for the
PTV and the PRV-OARs were measured and analyzed.
Results: Treatment plans generated using VMAT had better PTV homogeneity than the IMRT plans. For the PRV-OARs,
the 1-arc VMAT had significantly higher Dmean and V5 for left lung and heart, and showed worse Dmean for liver,
esophagus, spinal cord, contralateral lung and breast. In contrast, the 2-arc VMAT and the 2-F or 4-F IMRT plans showed
better results for the PRV-OARs than the 1-arc VMAT. However, for the heart and coronary artery, the 1-arc VMAT
showed better V20 and V40 compared with the other plans. Moreover, the 2 F-IMRT had specially advantage on V5
and V20 for heart and V5 for coronary arteries, the 2-F IMRT also showed a greater MU and treatment times. Using the
table of quality score to evaluate the plans, we found that 2-F IMRT had the highest scores of 13, followed by the 2-arc
VMAT plan (10 points) and 1-arc VMAT plan (8 points), and finally the 4-F IMRT plan (6 points). Moreover, when a dose
comparison for heart minus coronary artery was calculated, the V20 and V40 for the rest of heart in all plans were very
small and closed, indicating the dose to the coronary artery contributed dramatically to the high dose volumes for the
entire heart.
Conclusions: Compared to other plans, the 2-F IMRT plan with fewer monitor units and shorter delivery time is an
appropriate technique for left sided breast cancer, which achieved good PTV coverage and sparing of organs at risk
besides for the heart and coronary artery.
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Introduction
Breast cancer is the most common cancer among
women. About 1.2 million women are newly diagnosed
with breast cancer each year in the world, and 500,000
women die of it each year. Therefore, the breast cancer
remains the primary cause of cancer mortality in women
after lung cancer. A number of randomized controlled
clinical trials have shown that breast-conserving surgery
(BCS) combined with post-operative radiation therapy
(PORT) [1] has the same curative effect as the Halsted
radical mastectomy [2], making this the primary thera-
peutic strategy for Stages I and II breast cancer. PORT
has been shown to substantially reduce the rate of local
relapse and improve long-term survival [3] but at the
cost of morbidity to the heart [4], lung [5] and a risk of
secondary breast cancer [6]. Among these Organs at
Risk (OARs), the heart is one of the most important, in
particular in relation to radiotherapy for left-sided breast
cancer where cardiac dose has been associated with
increased cardiac mortality [7, 8].
Three-dimensional conformal radiation therapy (3-D
CRT) and intensity-modulated radiation therapy (IMRT)
techniques have been implemented across China.
Traditionally, breast radiotherapy used a fluoroscopic
technique with two dimensional planning. This was
followed by 3-D CRT with two conventional tangential
radiotherapy fields. IMRT has been widely used for
the past decade, permitting variation of fluence across
the radiotherapy fields, and allowing optimal dose
distribution according to an individual’s anatomy. It
has been suggested that IMRT results in improved
dose homogeneity within the irradiated breast with
added sparing of the heart and lung when compared
with 3-D CRT [9, 10]. Breast IMRT ranges from photon-
only IMRT to mixed electron and photon IMRT with 2 to
16 fields of various photon and electron beam energies
[11]. Dogan et al. [12] investigated the number of beams
necessary for optimal dose coverage of the breast and
found that 4-field IMRT was the best choice. A newer
technique known as volumetric modulated arc therapy
(VMAT) was introduced in 2007 as a novel extension of
IMRT, in which an optimized three-dimensional dose
distribution could be delivered in a single gantry rotation.
Compared to IMRT planning, VMAT resulted in even
better Planning Target Volume (PTV) coverage and
sparing of OARs than IMRT [13]. However, Badakhshi et
al. argued that VMAT was inferior to IMRT and 3D-CRT
with regard to dose distribution to organs at risk, especially
at the low dose level, therefore VMAT was not recom-
mended for breast cancer treatment compared with IMRT
or conventional radiotherapy [14]. To further assess the
advantages and the disadvantages of different IMRT and
VMAT plans in whole left breast irradiation for the breast
cancer patient, the VMAT (1 and 2-arc VMAT) plans and
IMRT (2 and 4-field IMRT) plans were examined in a
prospective clinical setting to adequately evaluate the
irradiated dose analysis of planning target volume and
OARs, especially focusing on heart coronary artery (CA).
Material and methods
Patients
Eleven patients with stage 0 (two patients), stage I (five
patients) and stage II (four patients: two patients were
diagnosed with N1) left-sided breast cancer were randomly
selected for this treatment planning study. They had under-
gone breast-conserving surgery. The mean patient age at
treatment was 45 years (range from 32 to 67 years). This
study was approved by the Research Ethics Board of the
China-Japan Union Hospital of Jilin University, and all
patients agreed to the conditions of this trial. Completed
informed consent forms were obtained from each patient.
Target and normal tissue delineation
The breast Clinical Target Volume (CTV) included all
visible breast parenchyma, retracted 5 mm from the skin
surface. The Planning Target Volume (PTV) comprised
the CTV with a 7 mm circumferential margin to allow for
daily set-up variations and account for setup uncertainties
and respiratory motion, and was also retracted 5 mm from
the skin surface. The breast PTVs ranged from 149 cm3 to
537 cc (296.6 ± 122.2 cc).
The Planning Risk Volume (PRV) of all the involved
OARs, including contra-lateral breast, entire heart,
coronary artery area, liver, spinal cord, esophagus, left
lung and right lung were outlined by the treating physician.
According to the American Memorial Sloan-Kettering
Cancer Research Methods (AMSK CRM), one-fourth of
the left anterior aspect of the heart, up to 1 cm subsurface,
is identified as the volume encompassing the coronary
artery (CA) area [15].
Planning procedure
Both VMAT and step and shoot IMRT plans were
completed in the three-dimensional treatment planning
system (TPS) Monaco® v.3.20.02 Elekta AB, Stockholm,
Sweden). The TPS determines densities in the body based
on CT density calibration curves, and calculates dose with
a Monte Carlo Photon algorithm, taking into account the
calibration for an inhomogeneous medium. An Elekta
Synergy® (Elekta AB, Stockholm, Sweden) linear accelerator
fitted with the Multi Leaf Collimator MLCi™ (1 cm leaf
width) was used with a 6 MV photon energy beam. All
plans were normalized to the 95 % isodose line
encompassing 95 % of the PTV (V95 % = 47.5 Gy).
The 2-F IMRT plan used two opposed modulated fields,
which suited the PTV curved shape and orientation. The
gantry angle was determined according to the angle of the
curve formed by the PTV. On the basis of the 2-F IMRT,
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the 4-F IMRT plan added two modulated fields, thereby
better avoiding the coronary artery area. A 2-arc VMAT
(4 shuttle subarcs) plan was generated using two small 40°
rotations (the gantry angle of middle line of the arc was
identical with the direction with the 2-F IMRT and was
same with it) which followed the orientation of the 2-F
IMRT. The 1-arc VMAT (2 shuttle subarcs) plan was
generated using a single 210°rotation with a starting angle
and ending angle similar to that of the 4-F IMRT. This
sector angle was used to avoid entrance doses to the
contralateral lung and heart. The minimum subarc
segment area was 2 cm2; the minimum number of monitor
units was four; the maximum number of control points per
arc was 60; the minimum segment width was 1 cm, and the
fluence smoothing was at medium level. The four-field
arrangements are shown in Fig. 1, and use the same
optimization objective. Optimization prioritized normal
tissue constraints, and used segment shape optimization.
Prescribed dose
The prescription dose to the whole breast was 50 Gy in
25 fractions (D50 = 50 Gy) according to the ICRU report
number 83 recommendations [16]. The prescription
properties are shown in Table 1 under Monaco system.
We used a 10 Gy electron boost to the tumor bed after
delivery of 50 Gy to the entire breast (not included in
the doses analyzed).
Dosimetric evaluation parameters
The following parameters were evaluated to assess plan
quality: for the PTV, the dose to 98 and 2 % of the
volume (D98 % and D2 %, respectively) and the part of
the PTV receiving more than 107 % of the prescribed
dose (V107 %) were explicitly calculated. Additionally,
the Homogeneity Index (HI) was calculated according
to ICRU 83 [17]: HI = (D2 %–D98 %)/D50 %. The Con-
formity Index (CI) as proposed by Paddick et al. [18]
was evaluated: CI = V47.5/PTV. The Conformity Number
(CN) = (VPTV47.5/VPTV)*(VPTV47.5/VBody47.5), and integral
dose (ID) = VBody*DMean in body, outside PTV were also
reconstructed. Total treatment delivery time was measured
on the quality assurance model in phantom and recorded
from end of phantom setup to the end of the treatment,
not including the idle frame time. The primary field
switching system could trigger automatically.
Plans of quality analysis in population and individual case
To better summarize the most superior technique from the
multi-parameter results of our study, we use the quality
score table of the plans for evaluation. The parameter
setting in the table was chosen according to the weight
factors of our concerning in our research. In the score table,
it is scored to point 1 if one parameter showed significant
advance (p < 0.05) comparing with another parameter
among the different plans, otherwise scored to 0. And only
the best index/indices could get 1 point in each parameter.
Moreover, we used individual plan comparison table
for evaluating the technique in each parameter/patient
by tabulating the number of the patients and record-
ing or calculating the best plan (with favorable index
among the four plans).
Fig. 1 IMRT and VMAT treatment plans with corresponding examples of segment shapes and digitally reconstructed radiographs (DRRs) for left-sided
breast cancer
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Statistics
All results were compared and analyzed using a two-
sided paired t test by SPSS 11.5 software, and a statistical
significance level of 0.05 was used (p < 0.05).
Results
Dose analysis of planning target volume
Figure 2 shows axial dose distributions with VMAT and
IMRT. Both VMAT and IMRT achieved 95 % coverage
of the PTVs. Mean values for HI, CI and CN are
presented in Table 2. We found that both VMAT and
IMRT achieved good dose homogeneity across the whole
breast for all patients in this study. The two VMAT
plans have better HI and CI than the two IMRT plans,
and decreased V107, too. However, the difference in HI
and CI was not significant between any two IMRT or
VMAT plans.
MUs and delivery time
Table 2 also shows that MUs and the estimated treat-
ment time per 2 Gy fraction for the 2-F IMRT plan was
significantly lower than other three plans. With respect
to the both MUs and the treatment time, the values for
1-arc VMAT plans were the worst.
Dose analysis of OARs
The Dmean in healthy tissue (outside of the PTV)
increased in the plans, from the 2-F IMRT, to 2-arc
VMAT, to the 4-F IMRT, to the 1-arc VMAT (Table 3).
The Dmean and VGy (the volume of the organ receiving
at least a given dose (Gy)), for the left and right lungs,
contralateral breast, esophagus, spinal cord and liver in the
different treatment techniques are shown in Table 3. For
left lung, the Dmean was similar for two IMRT and 2-arc
VMAT, but worse for 1-arc VMAT. The 2-F IMRT plan
reduced the volumes receiving low dose (V5), but
increased the volumes receiving high doses (V40)
compared with other plans. However, the 1-arc VMAT
plan showed better results than other plans for left lung at
V40 with statistical significance. The difference of V5-V40
between the 2-arc VMAT and the 4-F IMRT plan was not
statistically significant.
Compared with the other plans for the other OARs,
the 1-arc VMAT plan significantly increased the Dmean
and V5 of the right lung and breast, and also the Dmean
of esophagus, liver and spinal cord. Among the 2-F
IMRT, 4-F IMRT and 2-arc VMAT plan, there was no
statistically significant difference in these organs.
Detailed results are given in Table 3.
Table 1 The prescription properties of the IMRT and VMAT plans
Structure Cost Function Constraints
PTV Target Penalty Prescription:5000 cGy Minimum Volume:50 % Surface Margin:0.5 cm
Quadratic Overdose Maximum Dose:5150 cGy RMS Dose Excess:50 cGy Shrink Margin:0.00 cm
Underdose DVH Objective Dose:4750 cGy Minimum Volume:95 %
Coronary Artery Overdose DVH Objective Dose:500 cGy Maximum Volume:76 % Shrink Margin:0.5 cm
Overdose DVH Objective Dose:1000 cGy Maximum Volume:55 % Shrink MarginL:0.2 cm
Overdose DVH Objective Dose:2000 cGy Maximum Volume:46 % Shrink MarginL:0.1 cm
Left Lung Maximum Dose Maximum Dose:4950 cGy Shrink Margin:0.8 cm
Overdose DVH Objective Dose:500 cGy Maximum Volume:30 % Shrink Margin:0.0 cm
Optimize over all voxels in volume
Overdose DVH Objective Dose:1000 cGy Maximum Volume:20 % Shrink Margin:0.0 cm
Overdose DVH Objective Dose:2000 cGy Maximum Volume:15 % Shrink Margin:0.0 cm
Heart Overdose DVH Objective Dose:3000 cGy Maximum Volume:3 % Shrink Margin:1.0 cm
Right Breast Overdose DVH Objective Dose:500 cGy Maximum Volume:4 % Shrink Margin:0.3 cm
Right Lung Overdose DVH Objective Dose:500 cGy Maximum Volume:6 % Shrink Margin:0.0 cm
Liver Maximum Dose Maximum Dose:1500 cGy Shrink Margin:0.8 cm
Esophagus Maximum Dose Maximum Dose:500 cGy Shrink Margin:0.0 cm
Spinal cord Maximum Dose Maximum Dose:800 cGy Shrink Margin:0.5 cm
Body Quadratic Overdose Maximum Dose:5000 cGy RMS Dose Excess:30 cGy Shrink Margin:0.00 cm
Quadratic Overdose Maximum Dose:4500 cGy RMS Dose Excess:40 cGy Shrink Margin:1.00 cm
Maximum Dose Maximum Dose:6050 cGy Shrink Margin:0.00 cm Optimize over all voxels in volume
Maximum Dose Maximum Dose:5600 cGy Shrink Margin:0.50 cm
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Dose analysis of heart and coronary arteries
Comparisons for the relevant dosimetric parameters for
heart and coronary artery are given in Table 4. The mean
dose to the entire heart was smaller for the IMRT plans
compared with VMAT plans, but the mean dose to the
coronary artery (CA) was similar in all plans. For the heart
and CA, the 2-F IMRT plan reduced the V5 compared
with other plans. The 1-arc VMAT plan was worse for V5,
but showed good result for V20 and V40 compared with
other plans. The 2-arc VMAT plan slightly increased the
V20 and V40, but no difference was seen compared with
the IMRT plans. For dose comparison of the region of
interest: entire heart minus coronary artery, the V20 in all
the plans was less than 1 % and not significantly different
between any two.
Plans of quality score
From the summary of scoring (Table 5), we found that 2-F
IMRT had the highest scrores of 14 with 4 points from
heart and CA, followed by the 2-arc VMAT plan (10
points) with none from heart and CA, and the 1-arc VMAT
plan (8 points) with the 4 points from heart and CA, finally
Table 2 PTV dose parameters for four plans
2FIMRT 4FIMRT 2ArcVMAT 1ArcVMAT
D98 (Gy) 46.2 ± 0.6 A 46.4 ± 0.4 46.6 ± 0.4 B 46.6 ± 0.6 B
D50 (Gy) 50.7 ± 0.5 A 50.2 ± 0.3 B,a 49.7 ± 0.5 B,b 49.7 ± 0.6 B,b
D2 (Gy) 53.8 ± 0.7 A 53.5 ± 0.5 A 52.5 ± 0.6 B 52.5 ± 1.1
V107 4.6 % ± 5.4 % A 2.2 % ± 1.8 % a 0.6 % ± 1.1 % B 0.7 % ± 0.9 % B,b
HI 0.150 ± 0.022 A 0.140 ± 0.016 A 0.118 ± 0.018 B 0.120 ± 0.029 B
CI 1.34 ± 0.10 A 1.32 ± 0.10 A 1.24 ± 0.07 B,a 1.16 ± 0.05 B,b
CN 0.677 ± 0.050 A 0.685 ± 0.051 A 0.728 ± 0.036 B,a 0.781 ± 0.032 B,b
MU 265.8 ± 15.6 A,b 353.1 ± 41.0 A,a 494.1 ± 54.5 B,b 598.3 ± 93.9 B,a
Time
(Second)
115.8 ± 10.0 A 206.3 ± 25.0 B,a 160.9 ± 17.6 B,b 189.1 ± 27.0 B,a
“A” is statistically significantly different from “B” (p < 0.05); “a” is statistically significantly different from “b” (p < 0.05). No other statistically significant difference
was found between any two (p > 0.05)
Fig. 2 Isodose distributions for IMRT and VMAT treatment plans
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the 4-F IMRT plan (6 points) with 2 points from heart and
CA. From the individual plan comparison (Table 6), we
found that 2-F IMRT plan showed advantage on multiple
indices for almost patients. And for heart and CA, the 2-F
IMRT and 1-arc VMAT also showed equally “most appear-
ance score” on indices (both 3 point) (Table 6). These re-
sults suggested that there might be a clinical advantage for
using 2-F IMRT over other plans in overall consideration.
Discussion
Planning comparisons and dosimetric studies of different
field IMRT or VMAT in breast cancer have been
evaluated in a large number of studies and there’s always
been a debate on employing which technique in the
radiation practice. This study compares different arcs of
VMAT and fields of IMRT in radiotherapy planning, and
evaluates the plans with the quality score table which
focused on heart dose and coronary area in left sided
breast cancer radiotherapy. However, the advantage of
suitable radiotherapy plan for the patients with relative
smaller breast has not been fully clarified.
Patients with early stage left breast cancer could survive
for a long time and adapt to receive techniques that may
reduce the incidence of acute and late toxicity induced by
Table 3 Dose comparison of the ipsilateral lung, the contralateral lung, contralateral breast, liver, esophagus, and spinal cord in the
four plans
Structure Dose parameter 2FIMRT 4FIMRT 2ArcVMAT 1ArcVMAT
Body-PTV Dmean(Gy) 2.2 ± 0.7
A 2.4 ± 0.7 A 2.3 ± 0.7 A 2.8 ± 0.8 B
ID (Gy*litre) 43.7 ± 13.5 A 48.0 ± 13.9 B,a 44.7 ± 13.6 A,a 54.5 ± 16.7 B,b
Left Lung Dmean(Gy) 4.9 ± 2.4
A 5.2 ± 2.1 5.0 ± 2.0 A 5.4 ± 1.8 B
V5 16.6 % ± 7.9 % A 19.1 % ± 7.7 % B 18.4 % ± 7.2 % B,a 21.7 % ± 6.9 % B,b
V20 9.3 % ± 5.1 % 9.5 % ± 4.7 % 9.2 % ± 4.2 % 9.3 % ± 4.1 %
V40 4.3 % ± 2.8 % A 3.7 % ± 2.3 % B,a 3.8 % ± 2.2 % a 3.1 % ± 1.9 % B,b
Right lung Dmean (Gy) 0.2 ± 0.1
A 0.3 ± 0.2 A 0.3 ± 0.1 A 0.8 ± 0.4 B
V5 0.0 % ± 0.0 % A 0.4 % ± 1.0 % 0.0 % ± 0.1 % a 0.9 % ± 1.5 % B,b
Right breast Dmean(Gy) 0.5 ± 0.3
A 0.8 ± 0.4 B,a 0.9 ± 0.3 B,a 1.8 ± 0.8 B,b
V5 0.1 % ± 0.2 % A 1.9 % ± 1.9 % B,a 0.6 % ± 1.1 % B,b 1.5 % ± 2.3 % B
Esophagus Dmean(Gy) 0.3 ± 0.1
A 0.4 ± 0.1 A 0.4 ± 0.1 A 0.7 ± 0.3 B
Liver Dmean(Gy) 0.2 ± 0.1
A 0.2 ± 0.1 A 0.3 ± 0.2 A 1.0 ± 0.7 B
Spinal cord Dmean(Gy) 0.1 ± 0.0
A 0.2 ± 0.0 A 0.2 ± 0.0 A 0.4 ± 0.2 B
“A” is statistically significantly different from “B” (p < 0.05); “a” is statistically significantly different from “b” (p < 0.05). No other statistically significant difference
was found between any two (p > 0.05)
Table 4 Dose comparison of the heart, coronary artery and heart minus coronary artery in the four plans
Structure Dose parameter 2FIMRT 4FIMRT 2ArcVMAT 1ArcVMAT
Heart Dmean(Gy) 2.8 ± 1.0
A 3.0 ± 1.4 a 3.3 ± 1.3 B 3.7 ± 1.4 B,b
Dmax(Gy) 50.2 ± 2.3
A 48.2 ± 3.7 B,a 44.1 ± 15.7 45.4 ± 5.2 B,b
V5 8.6 % ± 3.8 % A 11.0 % ± 6.9 % a 13.7 % ± 7.0 % B 16.6 % ± 9.2 % B,b
V20 3.4 % ± 1.7 % A 3.3 % ± 2.3 % A 3.7 % ± 2.4 % B 3.4 % ± 2.6 % A
V40 0.9 % ± 0.5 % A 0.7 % ± 0.5 % B 0.9 % ± 0.6 % a 0.4 % ± 0.5 % B,b
CA Dmean(Gy) 13.2 ± 3.9 13.3 ± 4.0 12.7 ± 5.8 12.7 ± 4.3
Dmax(Gy) 50.2 ± 1.7
A 48.7 ± 3.7 A 48.9 ± 5.3 A 45.6 ± 4.9 B
V5 56.4 % ± 15.4 % A 60.8 % ± 16.6 % 62.1 % ± 18.6 % B 62.7 % ± 15.2 % B
V20 26.1 % ± 10.5 % 25.7 % ± 10.9 % 27.2 % ± 12.3 % A 24.8 % ± 13.3 % B
V40 7.3 % ± 3.8 % A 5.9 % ± 3.5 % A 6.8 % ± 4.0 % A 3.3 % ± 3.5 % B
Heart-CA Dmean(Gy) 1.4 ± 0.5
A 1.8 ± 0.9 B,a 2.0 ± 0.9 B,a 2.5 ± 1.0 B,b
V5 2.4 % ± 2.0 % A 5.6 % ± 5.3 % B,a 7.3 % ± 6.1 % B 10.5 % ± 8.5 % B,b
V20 0.3 % ± 0.6 % 0.6 % ± 1.2 % 0.6 % ± 1.2 % 0.6 % ± 1.1 %
V40 0.1 % ± 0.2 % 0.1 % ± 0.2 % 0.1 % ± 0.2 % 0.0 % ± 0.1 %
“A” is statistically significantly different from “B” (p < 0.05); “a” is statistically significantly different from “b” (p < 0.05). No other statistically significant difference
was found between any two (p > 0.05)
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radiotherapy. The cardiovascular complications induced
by radiation- as a main radiotherapy-related late toxicity
event progresses over time, and may manifest decades
after the initial exposure [19]. The coronary artery injury
was considered to be the most serious radiation-related
complication in the heart. Darby SC et al. reported that
exposure of the heart to ionizing radiation during radio-
therapy for breast cancer increases the subsequent rate of
ischemic heart disease linearly with the mean dose to the
heart by 7.4 % per gray, with no apparent threshold [20].
Other studies further suggested that 1 Gy irradiation added
to the mean heart dose could increase the cardiotoxic risk
by 4 % [21]. Several studies had observed substantial
radiation-induced heart disease when the heart receives
more than 40 Gy and that the reduction of the V40 was
pertinent in reducing heart toxicities [22, 23]. In the present
study, when calculated the scores from the sections of heart
and coronary arteries, we found that both the 1-arc VMAT
and 2-F IMRT have the highest scores of 4 points. The
former showed advantage on V20 and V40 for heart
and coronary arteries, and the latter showed favorable
results on Dmean, V5 and V20 for heart and V5 for
coronary arteries. This meant the 2-F IMRT and 1-arc
VMAT plan showed a statistically significant improve-
ment for heart dose for left-sided breast irradiation.
Nowadays, the developed radiation techniques could
also be used to spare the cardiac area sparing in breast
radiation practice. It was reported that radiation deliver-
ing in Deep Inspiration Breath Hold (DIBH) conditions
could reduce the dose to heart for left-sided breast
cancer patients [24]. Some other studies demonstrated
that whole breast irradiation with prone position seems
to be beneficial for 85 % of the patients regarding heart
irradiation [25]. Further studies found that IMRT with
prone position is superior to supine treatment for right-
sided breast cancer patients and left-sided breast cancer
patients with larger breasts [26] and benefited most from
prone position with DIBH for heart sparing by radiation
dose [27]. But for patients of smaller breast volume in
left side, some studies argued that the prone position
might result in worse cardiac dosimetry than supine
position [28, 29].
Table 5 Plan score table of the four treatment techniques
Structure Dose Parameter 2 F-IMRT 4 F-IMRT 2Arc-VMAT 1Arc-VMAT
PTV HI 0 0 1 1
CI 0 0 1 1
CN 0 0 1 1
MU 1 0 0 0
Time 1 0 0 0
Lung.L Dmean 1 0 1 0
V5 1 0 1 0
V20 0 0 0 0
V40 0 0 0 1
Heart Dmean 1 1 0 0
V5 1 0 0 0
V20 1 1 0 1
V40 0 0 0 1
Coronary artery Dmean 0 0 0 0
V5 1 0 0 0
V20 0 0 0 1
V40 0 0 0 1
Healthy tissue Dmean 1 1 1 0
Breast.R Dmean 1 0 0 0
Liver Dmean 1 1 1 0
P-cord Dmean 1 1 1 0
Eso Dmean 1 1 1 0
Lung.R Dmean 1 0 1 0
Total Score 14 6 10 8
Scores from Heart and CA 4 2 0 4
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Moreover, when a dose comparison of heart minus
coronary artery calculated, the observed V20 and V40
for the rest of heart, in all plans were very small and
closed, suggesting that the dose volume for the coronary
arteries can be used to predict the dose volume of the
high dose for the entire heart.
For other OARs, it has been reported that the doses to
the ipsilateral lung have been shown to be responsible for
radiation pneumonia in breast cancer radiotherapy [30].
Dosimetric parameters of mean lung dose and V20
showed a significant correlation with the development of
radiation-induced pneumonitis in radiotherapy for breast
cancer [31, 32]. In our study, we found that for Dmean and
V5 to ipsilateral lung, the best results were from 2-F IMRT
and 2-arc VMAT plans, and the V20 to the ipsilateral lung
was uneventful in all plans. In addition, the 2-F IMRT, 4-F
IMRT and 2-arc VMAT plans were associated with the
most favorable dose deposition in the liver, esophagus,
spinal cord, contralateral lung compared with 1-arc VMAT.
Except for acute and late radiation damage induced by
high dose radiation, the low dose irradiation raises the
concern of radiation-induced secondary malignancy [33].
The delivery of low-dose irradiation to healthy tissue,
especially to the contralateral breast, has been estimated
to double the risk of subsequent malignancy [34], and
this risk increases with increasing dose [15]. Based on
our study, it was demonstrated that 2-F IMRT and 2-arc
VMAT resulted in a reduction of the mean dose to
healthy tissue and ID as compared with that in other
plans. And the 2-F IMRT plan also showed advantage
on Dmean in contralateral breast.
So from the overall consideration we suggest to choose
2-F IMRT with the highest scores which was suitable for
the protection of heart and coronary artery in left-sided
breast cancer radiotherapy. We also found that 2-arc
VMAT technique with the second highest scores could
improve the homogeneity and conformity in PTV and
sparing of some OARs in some dosimetric indications. So
if the doctor has not concerns on the heart and coronary
artery, the 2-arc VMAT technique may also be a good
choice. The 1-arc VMAT plan with fewer composite
scores has apparent advantages on Dmax and high doses
regions to heart and coronary artery, which might also be
a selective plan for sparing heart dose in practice. The 4-F
Table 6 Individual plan comparison table
Structure Parameter 1 2 3 4 5 6 7 8 9 10 11 Most Appearance
PTV HI 2A 2A 4 F 2A 2A 1A 1A 1A 1A 2A 2A 2A
CI 1A 1A 1A 1A 1A 1A 1A 1A 1A 1A 1A 1A
CN 1A 1A 1A 1A 1A 1A 1A 1A 1A 1A 1A 1A
MU 2 F 2 F 2 F 2 F 2 F 2 F 2 F 2 F 2 F 2 F 2 F 2 F
Time 2 F 2 F 2 F 2 F 2 F 2 F 2 F 2 F 2 F 2 F 2 F 2 F
Lung.L Dmean 2 F 2 F 2 F 2 F 2 F 2 F 2A 2 F 2 F 1A 4 F 2 F
V5 2 F 2 F 2 F 2 F 2 F 2 F 2A 2A 2 F 1A 4 F 2 F
V20 2 F 2 F 2A 2 F 2 F 1A 1A 2A 1A 1A 4 F 2 F /1A
V40 4 F 1A 1A 4 F 1A 1A 1A 2A 4 F 1A 1A 1A
Heart Dmean 4 F 2 F 2 F 2 F 2 F 2 F 4 F 2A 4 F 1A 2 F 2 F
V5 2 F 2 F 2 F 2 F 2 F 2 F 4 F 2A 2 F 2 F 2 F 2 F
V20 4 F 4 F 4 F 2 F 4 F 4 F 4 F 2A 4 F 1A 1A 4 F
V40 1A 1A 1A 1A 4 F 1A 1A 1A 4 F 1A 1A 1A
CA Dmean 4 F 4 F 1A 2 F 4 F 1A 1A 2A 4 F 1A 1A 1A
V5 2 F 2 F 4 F 2 F 2 F 4 F 2 F 2A 4 F 1A 4 F 2 F
V20 4 F 4 F 4 F 2 F 4 F 4 F 1A 2A 4 F 1A 1A 4 F
V40 4 F 1A 1A 4 F 1A 1A 1A 1A 4 F 1A 1A 1A
Healthy tissue Dmean 2 F 2 F 2 F 2 F 2 F 2 F 2 F 2A 2 F 2A 2 F 2 F
Breast.R Dmean 2 F 2 F 2 F 2 F 2 F 4 F 2 F 2 F 2 F 2 F 2 F 2 F
Liver Dmean 2A 2A 2 F 2 F 2 F 4 F 2 F 2A 2 F 4 F 2 F 2 F
P-cord Dmean 2 F 2 F 2 F 2 F 2 F 2 F 2 F 2 F 2 F 4 F 2 F 2 F
Eso Dmean 2 F 2 F 2 F 2A 2 F 2 F 2 F 2A 2 F 2 F 2 F 2 F
Lung.R Dmean 2 F 2 F 2 F 2 F 2 F 2 F 2 F 2 F 2 F 2 F 2 F 2 F
Most Appearance 2 F 2 F 2 F 2 F 2 F 2 F 2 F/1A 2A 2 F 1A 2 F
Abbreviations: 1A 1-arc VMAT, 2A 2-arc VMAT, 2 F 2-F IMRT, 4 F 4-F IMRT
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IMRT plans did not show special advantages when
compared with other plans in our research.
Conclusion
In conclusion, compared with other plans, the 2-F IMRT
plan has demonstrated the combined advantages in PTV
dose coverage and dose drop to most normal tissue
involved in our research, besides for the heart and coronary
artery. So we suggest employing 2 F-IMRT plan for left
breast cancer radiotherapy after breast-conserving surgery.
Consent
Written information consent was obtained from the patient
for publication of this report and any accompanying
images.
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